A Safety Study of SGN-35C in Adults With Advanced Cancers

Phase 1

Recruiting

• Conditions: Lymphoma, T-Cell, Peripheral; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Lymphoma, Large-Cell, Anaplastic
• Interventions: Drug: SGN-35C

• Registration Number: NCT06254495
• Lead Sponsor: Seagen Inc.

Brief Summary

This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma. This study will enroll people who have classical Hodgkin lymphoma (cHL), peripheral T cell lymphoma (PTCL), or diffuse large B cell lymphoma (DLBCL).
...

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2024-02-02
• Study First Submitted QC: 2024-02-02
• Study First Posted: 2024-02-12
• Study Start: 2024-05-28
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-12
• Last Update Posted: 2024-11-13
• Primary Completion: 2028-02-28
• Study Completion: 2028-08-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 170

Inclusion Criteria

• Tumor type

• For dose escalation and dose optimization (Parts A and B):

  • Participants with a histologically confirmed lymphoid neoplasm who in the judgement of the investigator have no appropriate standard therapy available at the time of enrollment and are a candidate for SGN- 35C treatment. Eligible subtypes and treatment status are as follows:

    • Participants with relapsed/refractory (R/R) cHL: should have received at least 3 prior systemic therapies including autologous stem cell transplant [ASCT] (ASCT and the associated high-dose chemotherapy prior to ASCT are considered to be 1 prior line) or an anti-PD-1 agent (or refused/were ineligible); or 2 prior systemic therapies if, according to the investigator, no other appropriate standard treatment is available.
    • Participants with R/R PTCL (excluding systematic anaplastic large cell lymphoma [sALCL]): should have received at least 2 prior systemic therapies, or 1 prior systemic therapy if, according to the investigator, no other appropriate standard treatment is available.
    • Participants with R/R sALCL: should have received at least 2 prior systemic therapies, including 1 brentuximab vedotin-containing regimen, or 1 prior line of systemic therapy including brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone.
    • Participants with R/R DLBCL: should have received at least 2 prior systemic therapies, including ASCT and chimeric antigen receptor (CAR) T-cell therapy, or were ineligible, or refused.

  • Participants with PTCL and DLBCL must have a detectable cluster of differentiation 30 (CD30) expression level (≥1%) in tumor tissue from the most recent biopsy obtained at or after relapse by local testing.

• For dose expansion (Part C):

  • Participants are eligible irrespective of CD30 expression on tumor tissue; however, participants must provide tumor tissue for evaluation of CD30 expression from the most recent biopsy obtained at or after relapse.
  • Participants with cHL, PTCL, sALCL, and DLBCL: Eligible subtypes are the same as defined in Parts A and B
  • If activated, the biology cohort may enroll the populations included in Parts A, B, and C.

• Eastern Cooperative Oncology Group (ECOG) Performance Status score of ≤1

• Fluorodeoxyglucose positron emission tomography (FDG-PET) avid and bidimensional measurable disease as documented by radiographic technique (spiral computed tomography [CT] preferred)

Read More

Exclusion Criteria

• Previous exposure to any antibody-drug conjugates (ADCs) with camptothecin-based payload.

• History of another malignancy within 3 years before the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death

• Active cerebral/meningeal disease related to the underlying malignancy

• Received previous ASCT infusion <12 weeks prior to the first dose of SGN-35C.

• Previous allogeneic stem cell transplant (SCT) if they meet any of the following criteria:

  • <100 days from allogeneic SCT. Participants ≥100 days from allogeneic SCT who are stable without immunosuppressive therapy for at least 12 weeks are permitted.
  • Active acute or chronic graft-versus-host disease (GVHD) or receiving immunosuppressive therapy as treatment for or prophylaxis against GVHD.

• History of clinically significant GI bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of trial treatment.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SGN-35C	SGN-35C	SGN-35C Monotherapy

Primary Outcome Measures

Name	Time	Method
Number of participants with adverse events (AEs)	Through 30-37 days after last study treatment, approximately 1 year	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention , whether or not considered related to the study intervention
Number of participants with laboratory abnormalities	Through 30-37 days after last study treatment, approximately 1 year
Number of participants with DLTs by dose level	Up to 21 days
Number of participants with dose modifications due to AEs	Up to approximately 1 year
Number of participants with dose-limiting toxicities (DLTs)	Up to 21 days

Secondary Outcome Measures

Name	Time	Method
Number of participants with antidrug antibodies (ADA)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
Maximum concentration (Cmax)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
CR rate as assessed by the investigator	Up to approximately 1 year	CR rate is defined as the proportion of participants with CR.
Area under the concentration time curve (AUC)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
Time at which the maximum concentration occurs (Tmax)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
Apparent terminal half-life (t1/2)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
Trough concentration (Ctrough)	Through 30-37 days after last study treatment, approximately 1 year	To be summarized using descriptive statistics
Objective response rate (ORR) as assessed by the investigator	Up to approximately 1 year	A participant is determined to have an objective response if, based on Lugano criteria (Cheson 2014), they achieve a complete response (CR) or partial response (PR) as assessed by the investigator. The ORR is defined as the percentage of participants with an objective response.
Duration of response (DOR)	Up to approximately 1 year	DOR is defined as the time from the start of the first documentation of objective tumor response (CR or PR) to the first documentation of tumor progression per Lugano criteria (Cheson 2014) as assessed by the investigator or to death due to any cause, whichever comes first.

Trial Locations

Locations (9)

Rigshospitalet University Hospital of Copenhagen; 🇩🇰 Copenhagen, Other, Denmark

City of Hope; 🇺🇸 Duarte, California, United States

UC San Diego / Moores Cancer Center; 🇺🇸 La Jolla, California, United States

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies; 🇺🇸 San Francisco, California, United States

University of Miami; 🇺🇸 Miami, Florida, United States

University of Kansas Cancer Center; 🇺🇸 Fairway, Kansas, United States

University of Nebraska Medical Center; 🇺🇸 Omaha, Nebraska, United States

Fred Hutchinson Cancer Research Center | Seattle, WA; 🇺🇸 Seattle, Washington, United States

Centro Ricerche Cliniche di Verona s.r.l.; 🇮🇹 Verona, Other, Italy